Condition
Ovarian Steroid Cell Tumor
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT01042522Phase 2Unknown
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
NCT00006227Phase 2Completed
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
NCT00748657Phase 2Completed
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
Showing all 3 trials